Concepedia

C. Droege

CD

Statistics

Publications

7

Citations

326

H-Index

7

Active since

1999

Affiliations

University Hospital of Basel(Current)

Kantonsspital Winterthur

Swiss Group For Clinical Cancer Research

Kantonsspital St. Gallen

Fribourg Development Agency

C. Droege is an author at University Hospital of Basel specializing in medicine, oncology, and pharmacology.

Publications per year

1999–2015

7

Publications

7

A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer

Miklos Pless, C. Droege, Roger von Moos et al. · Lung Cancer · 2013 · 103 citations

Medicine, Oncology, Pharmacology +11

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment

B.H.M. Lenfers, Tina Loeffler, C. Droege et al. · Annals of Oncology · 1999 · 76 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)

Richard Cathomas, Christian Rothermundt, Dirk Klingbiel et al. · Clinical Cancer Research · 2012 · 45 citations

Medicine, Oncology, Pharmacology +17

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Markus Joerger, Florent Baty, Martin Früh et al. · Lung Cancer · 2014 · 42 citations

Medicine, Clinical Sciences, Oncology +15

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

Francesco Zappa, C. Droege, Daniel Betticher et al. · Lung Cancer · 2012 · 32 citations

Medicine, Oncology, Pharmacology +13

1–5 of 7